← Back

BioAge Labs, Inc

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. Its technology platform and differentiated human datasets are designed to identify targets based on insights into molecular changes that drive aging. Its lead product candidate is BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor in Phase 1 clinical trials for atherosclerotic cardiovascular disease, diabetic macular edema, and geographic atrophy. The company also develops APJ agonists for obesity, including programs for oral and parenteral administration, and has a collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating biological mechanisms related to aging. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Country

USA

Sector

Pharmaceuticals

Themes

Metabolic Aging & Geroprotectors

Price · split & dividend adjusted

News & notes moving BIOA

Biotech & Genomic Medicine▼

BioAge Labs Q2 Net Loss Widens to $26.09 Million

BioAge Labs reported a wider second-quarter net loss of $26.09 million, or $0.58 per share, compared with a loss of $21.56 million, or $0.60 per share, a year earlier. Collaboration revenue edged up to $2.45 million from $2.41 million. The clinical-stage biopharmaceutical company expects topline data from the Phase 2 QUELL-CV trial of its lead candidate BGE-102 in the second half of 2026, and plans to initiate the Phase 1b/2a QUELL-DME trial in diabetic macular edema in mid-2026 with data anticipated in mid-2027. BioAge also intends to file its first Investigational New Drug application for an APJ program by year-end 2026. As of June 30, 2026, the company held approximately $381.3 million in cash, cash equivalents, and marketable securities, which it estimates will fund operations through 2029.

BIOA ▼

Biotech & Genomic Medicine

RTTNews·43dRead more →

Biotech & Genomic Medicine▲

BioAge Labs Initiates Phase 2 Cardiovascular Study for NLRP3 Inhibitor BGE-102

BioAge Labs has dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept study evaluating its oral NLRP3 inhibitor BGE-102 for cardiovascular risk reduction. The company previously reported first-quarter 2026 financial results, including collaboration revenue of $2.8 million and research and development expenses of $20.4 million. As of March 31, 2026, BioAge held approximately $384.9 million in cash, cash equivalents, and marketable securities. Phase 1 data for BGE-102 showed median reductions of 86% in hsCRP levels from baseline across evaluated dose groups, with no serious adverse events reported. A Phase 2 dose-ranging study in participants with elevated cardiovascular risk is planned to begin in mid-2026.

BIOA ▲

Biotech & Genomic Medicine

Insider Monkey·80dRead more →